Here are the 8-K filings from PROCEPT BioRobotics Corporation (PRCT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow PRCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRCT filings page.
PROCEPT BioRobotics reported third-quarter 2026 revenue of $98.3 million, up 18% from a year earlier. U.S. revenue was $85.8 million, up 16%; U.S. handpiece and consumables revenue was $53.9 million, up 21%, while U.S. system revenue was $24.7 million, flat. International revenue rose 32% to $12.5 million. U.S. procedures exceeded 13,400, up approximately 22%, and gross margin was 66%, compared with 65%.
Operating expenses were $92.5 million, compared with $77.2 million, reflecting investment in people, product development, clinical studies, and sales and marketing. Net loss was $26.5 million, versus $21.4 million, and adjusted EBITDA loss, a non-GAAP measure, was $9.8 million versus $7.4 million. Cash, cash equivalents and restricted cash totaled approximately $221.4 million as of September 30, 2026.
The company reaffirmed 2026 revenue guidance of $390 million to $410 million, representing 27% to 33% growth, and U.S. procedure guidance of 54,000 to 56,000, representing 25% to 29% growth. It reiterated gross margin of approximately 65% and adjusted EBITDA loss guidance of $35 million to $30 million.
PROCEPT BioRobotics Corp (PRCT) approved expanding its board from nine to ten members and appointed Dr. Michael Mack as an independent Class II director, effective immediately. His initial term expires at the 2029 annual meeting and continues until his successor is elected and qualified, or until his earlier death, resignation or removal. Dr. Mack is a cardiac surgeon who has practiced in Dallas since 1982 and has more than 1,100 peer-reviewed publications. He will be compensated consistently with the company’s other non-employee directors and will enter into its standard director and officer indemnification and advancement agreement. The company stated that there are no arrangements or understandings with other persons connected to the appointment and no transactions involving Dr. Mack requiring disclosure under related-party transaction rules.
PROCEPT BioRobotics Corp. (PRCT) entered into a third amendment to its Loan and Security Agreement with Canadian Imperial Bank of Commerce, extending the term loan maturity date by 12 months, from October 1, 2027 to October 1, 2028. The agreement otherwise remains in full force and effect and continues to be subject to the same affirmative and negative covenants previously disclosed.
PROCEPT BioRobotics reported second quarter 2026 revenue of $94.5 million, up 19% year over year, driven by higher U.S. handpiece, system and international revenue. U.S. revenue reached $83.4 million, with U.S. procedures over 13,100, an increase of approximately 21%. The company delivered 65 U.S. HYDROS systems, including 14 replacements, and handpieces represented about 98% of U.S. procedures.
Gross margin improved to 66%, supported by higher U.S. pricing and a $2.9 million tariff refund, while operating expenses rose to $89.8 million as the company invested in its commercial organization, BPH platform innovation and the WATER IV prostate cancer trial. Net loss widened to $26.9 million (adjusted EBITDA loss $11.3 million), and cash, cash equivalents and restricted cash totaled approximately $231 million at June 30, 2026.
For full year 2026, PROCEPT reiterates revenue guidance of $390 million to $410 million and gross margin of about 65%, expects U.S. procedure volume of 54,000-56,000, and now forecasts an adjusted EBITDA loss of $35 million to $30 million. Management also highlighted record HYDROS placements, completion of enrollment in the WATER IV study and a strengthened AUA guideline recommendation for Aquablation therapy.
PROCEPT BioRobotics Corporation held its annual stockholder meeting on June 9, 2026. Stockholders elected three directors—Antal Desai, Mary Garrett, and Frederic Moll, M.D.—to serve until the 2029 annual meeting, with each receiving over 28 million votes in favor.
Stockholders also ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 47,328,539 votes for, 21,691 votes withheld, and 23,133 abstentions. In addition, they approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 26,984,867 votes for, 9,924,704 votes withheld, 45,735 abstentions, and 10,418,057 broker non-votes.
PROCEPT BioRobotics reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Revenue rose 20% year over year to $83.1 million, driven by higher U.S. system and handpiece sales and 25% growth in international revenue. Gross margin improved to 65%, up from 64% a year ago and 61% in the prior quarter.
U.S. Aquablation procedures reached about 12,200, up roughly 30% year over year, and the U.S. install base grew to 765 systems, a 40% increase. Despite this growth, operating expenses increased to $86.6 million, leading to a net loss of $31.6 million and Adjusted EBITDA loss of $18.1 million. The company ended the quarter with about $249 million in cash and reaffirmed 2026 guidance, including revenue of $390–$410 million and an Adjusted EBITDA loss of $30–$17 million. PROCEPT also highlighted recent FDA clearance of its second-generation FirstAssist AI software, further enhancing its HYDROS robotic system.
PROCEPT BioRobotics Corporation reported that its board of directors increased in size from eight to nine members and appointed Daniel Puckett to fill the new seat. He is a Class III director, with an initial term running until the 2027 annual meeting of stockholders.
The board determined that Puckett qualifies as an independent director under SEC and Nasdaq rules and appointed him to the Audit Committee, effective immediately. He is a former Chief Financial Officer of Shockwave Medical, Counsyl and Ariosa Diagnostics, and will receive compensation consistent with other non‑employee directors.
PROCEPT BioRobotics used its Investor Day to outline rapid growth in Aquablation therapy for benign prostatic hyperplasia and a clearer path to profitability. Total revenue grew from $75M in 2022 to $309M in 2025, while gross margin expanded from 49.4% to 63.7%. U.S. Aquablation procedures rose to 43,300 in 2025 and the global install base reached 718 systems, implying Aquablation penetration of about 10% to 25% of the U.S. surgical market by management estimates.
The company is rolling out the next-generation HYDROS robotic platform, reorganizing its commercial model with dedicated launch teams, and investing heavily in clinical evidence, including the pivotal WATER IV prostate cancer trial. For 2026, it guides revenue of $390–$410M, gross margin of about 65%, and an adjusted EBITDA loss of $30–$17M, with a 2027 target of $25–$30M of adjusted EBITDA and 68–70% gross margin. Management highlights a strong balance sheet, modest capital needs, and expects to remain above $175M in cash while a $52M loan matures in 4Q27.
PROCEPT BioRobotics reported strong growth but wider losses for 2025 and reset its 2026 outlook. Q4 2025 revenue was $76.4 million, up 12%, with about 12,200 U.S. procedures and 65 new systems placed. Full-year 2025 revenue reached $308.1 million, a 37% increase, and gross margin improved to 64%, but net loss expanded to $95.6 million.
The U.S. install base grew 42% to 718 systems, while Q4 gross margin slipped to 61% due to lower-than-expected consumable revenue and a one-time field action. For 2026, the company guides revenue to $390–$410 million (27–33% growth), U.S. procedure growth of 39–48%, gross margin around 65%, operating expenses near $350 million, and an adjusted EBITDA loss between $30 million and $17 million. Cash and restricted cash totaled $289.5 million at year-end 2025.
PROCEPT BioRobotics Corporation filed a current report stating that it issued a press release announcing its financial results for the quarter ended September 30, 2025. The company used this report to make investors aware of the new earnings release without having the detailed numbers directly in the filing.
The press release, dated November 4, 2025, is attached as Exhibit 99.1 and is incorporated by reference, but is furnished rather than filed, which limits certain legal liabilities under securities laws. The company also included a cover page interactive data file in Inline XBRL format as Exhibit 104 to support electronic reporting and data analysis.
PROCEPT BioRobotics Corporation updated its form of Change of Control and Severance Agreement for executive officers below the CEO to better align with market data. The revised form increases severance for involuntary terminations not tied to a change of control from six months to twelve months, clarifies that performance-based awards accelerated on a change of control termination will be treated as achieved at no less than target performance, and changes change-of-control cash payments to be made in a single lump sum. The company will ask eligible executives to execute amended agreements consistent with the revised form and has filed the form as Exhibit 10.1.